The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global acne drugs market reached a value of US$ 4.82 Billion in 2020. Looking forward, IMARC Group expects the market to grow at a CAGR of 4.4% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Acne drugs refer to the medications used for treating a dermatological infection characterized by the inflammation in the hair follicles on skin. It is usually caused by hormonal imbalance, oily skin, accumulation of dead skin cells, bacteria, stress, inadequate intake of water and excessive consumption of sugars, salts or carbohydrates. Some of the commonly used acne drugs include topical medications, such as retinoids, salicylic and azelaic acid-based ointments and dapsone-based gels, along with antibiotics, anti-androgen agents and isotretinoin. These drugs minimize the levels of oil production in the body, speed up skin cell turnover, control acne breakouts, reduce scarring and damage to the skin and prevent inflammation.
The increasing prevalence of skin-related diseases, such as acne vulgaris, is one of the key factors driving the growth of the market. Moreover, rising awareness among the masses regarding the benefits of using premium skin care products is driving the market growth. The market is further being driven by the development of effective therapeutics and treatment alternatives with reduced side effects and high potential. Increasing consumer preference for products manufactured using natural ingredients is acting as another growth-inducing factor. Manufacturers are, therefore, developing products infused with natural herbs and organic ingredients, such as aloe vera, green tea, honey, jojoba oil and rosemary, for treating acne. Other factors, including rising expenditure capacities of consumers, along with the proliferation of online retail platforms that offer customized acne drugs according to the user’s skin type, are expected to create a positive outlook for the market.
Breakup by Acne Type:
Breakup by Drug Class:
Breakup by Drug Type:
Breakup by Route of Administration:
Breakup by Region:
The report has also analysed the competitive landscape of the market with some of the key players being Allergan Plc, Bausch Health Companies Inc., Bayer Aktiengesellschaft, Cipher Pharmaceuticals Inc., Galderma Holding SA, Johnson & Johnson, Pfizer Inc., Reckitt Benckiser Group Plc, Skinvisible Pharmaceuticals Inc., Sun Pharmaceutical Industries Limited and Teva Pharmaceutical Industries Ltd.
|Base Year of the Analysis||2020|
|Segment Coverage||Acne Type, Drug Class, Drug Type, Route of Administration, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Allergan Plc, Bausch Health Companies Inc., Bayer Aktiengesellschaft, Cipher Pharmaceuticals Inc., Galderma Holding SA, Johnson & Johnson, Pfizer Inc., Reckitt Benckiser Group Plc, Skinvisible Pharmaceuticals Inc., Sun Pharmaceutical Industries Limited and Teva Pharmaceutical Industries Ltd.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
Key Questions Answered in This Report:
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at